Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) - Total Assets
Based on the latest financial reports, Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) holds total assets worth TL3.82 Billion TRY (≈ $85.56 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Meditera Tibbi Malzeme Sanayi ve Ticaret (MEDTR) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Meditera Tibbi Malzeme Sanayi ve Ticaret AS - Total Assets Trend (2018–2025)
This chart illustrates how Meditera Tibbi Malzeme Sanayi ve Ticaret AS's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of Meditera Tibbi Malzeme Sanayi ve Ticaret to evaluate the quality of earnings relative to operating cash generation.
Meditera Tibbi Malzeme Sanayi ve Ticaret AS - Asset Composition Analysis
Current Asset Composition (December 2025)
Meditera Tibbi Malzeme Sanayi ve Ticaret AS's total assets of TL3.82 Billion consist of 50.7% current assets and 49.3% non-current assets.
| Asset Category | Amount (TRY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 8.8% |
| Accounts Receivable | TL760.92 Million | 21.2% |
| Inventory | TL550.44 Million | 15.3% |
| Property, Plant & Equipment | TL0.00 | 0.0% |
| Intangible Assets | TL14.39 Million | 0.4% |
| Goodwill | TL64.54 Million | 1.8% |
Asset Composition Trend (2018–2025)
This chart illustrates how Meditera Tibbi Malzeme Sanayi ve Ticaret AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Meditera Tibbi Malzeme Sanayi ve Ticaret market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Meditera Tibbi Malzeme Sanayi ve Ticaret AS's current assets represent 50.7% of total assets in 2025, a decrease from 75.3% in 2018.
- Cash Position: Cash and equivalents constituted 8.8% of total assets in 2025, up from 6.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 21.2% of total assets.
Meditera Tibbi Malzeme Sanayi ve Ticaret AS Competitors by Total Assets
Key competitors of Meditera Tibbi Malzeme Sanayi ve Ticaret AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
China | CN¥2.00 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
|
Shenzhen Lifotronic Technology Co
SHG:688389
|
China | CN¥2.53 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
Meditera Tibbi Malzeme Sanayi ve Ticaret AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.58 | 3.65 | 5.31 |
| Quick Ratio | 2.49 | 2.39 | 4.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | TL1.37 Billion | TL1.20 Billion | TL370.69 Million |
Meditera Tibbi Malzeme Sanayi ve Ticaret AS - Advanced Valuation Insights
This section examines the relationship between Meditera Tibbi Malzeme Sanayi ve Ticaret AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -2.4% |
| Total Assets | TL3.59 Billion |
| Market Capitalization | $63.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Meditera Tibbi Malzeme Sanayi ve Ticaret AS's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Meditera Tibbi Malzeme Sanayi ve Ticaret AS's assets decreased by 2.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Meditera Tibbi Malzeme Sanayi ve Ticaret AS (2018–2025)
The table below shows the annual total assets of Meditera Tibbi Malzeme Sanayi ve Ticaret AS from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | TL3.59 Billion ≈ $80.42 Million |
-2.38% |
| 2024-12-31 | TL3.68 Billion ≈ $82.38 Million |
+34.59% |
| 2023-12-31 | TL2.73 Billion ≈ $61.21 Million |
+148.57% |
| 2022-12-31 | TL1.10 Billion ≈ $24.63 Million |
+52.87% |
| 2021-12-31 | TL719.21 Million ≈ $16.11 Million |
+110.49% |
| 2020-12-31 | TL341.69 Million ≈ $7.65 Million |
+55.16% |
| 2019-12-31 | TL220.21 Million ≈ $4.93 Million |
+8.23% |
| 2018-12-31 | TL203.47 Million ≈ $4.56 Million |
-- |
About Meditera Tibbi Malzeme Sanayi ve Ticaret AS
Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi manufactures and sells medical devices in Turkey. The company offers two-way and single-line Infusion Systems; Chemotherapy Preparation and Administration Systems, such as medoconco automated drug preparation, diana semi-automatic drug dispensing, and ICU medical chemotherapy drug delivery systems; and respiratory systems products, includin… Read more